Eribulin versus S-1 as first or second-line chemotherapy to assess health-related quality of life and overall survival in HER2-negative metastatic breast cancer (RESQ study): a non-inferiority, randomised, controlled, open-label, phase 3 trial-Reference-Cited by-同舟云学术

Eribulin versus S-1 as first or second-line chemotherapy to assess health-related quality of life and overall survival in HER2-negative metastatic breast cancer (RESQ study): a non-inferiority, randomised, controlled, open-label, phase 3 trial

Published:2024-08 Issue: Volume:74 Page:102715
ISSN:2589-5370
Container-title:eClinicalMedicine
language:en
Short-container-title:eClinicalMedicine

Author:

Takahashi Masato^ORCID,Kikawa Yuichiro,Kashiwabara Kosuke,Taira Naruto,Iwatani Tsuguo,Shimozuma Kojiro,Ohtani Shoichiro,Yoshinami Tetsuhiro,Watanabe Junichiro^ORCID,Kashiwaba Masahiro,Watanabe Ken-ichi,Kitada Masahiro,Sakaguchi Koichi,Tanabe Yuko,Aihara Tomohiko,Mukai Hirofumi

Publisher

Elsevier BV

Reference33 articles.

1. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA Cancer J Clin,2021

2. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5);Cardoso;Ann Oncol,2020

3. Surrogate threshold effect based on a meta-analysis for the predictive value of progression-free survival for overall survival in hormone receptor-positive, HER2-negative metastatic breast cancer;Lux;Breast Cancer Res Treat,2019

4. Methodological and reporting standards for quality-of-life data eligible for European society for medical oncology-magnitude of clinical benefit scale (ESMO-MCBS) credit;Oosting;Ann Oncol,2023

5. Reporting of health-related quality of life (HRQOL) data in oncology trials: a comparison of the European organization for research and treatment of cancer quality of life (EORTC QLQ-C30) and the functional assessment of cancer therapy-general (FACT-G);Smith;Qual Life Res,2014